X0206 3 2020-12-03 0 0001466301 Clovis Oncology, Inc. CLVS 0001834833 Harding Thomas C. C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 3210 D Stock Option (right to buy) 73.98 2024-01-10 Common Stock 2167 D Stock Option (right to buy) 78.38 2024-02-27 Common Stock 30000 D Stock Option (right to buy) 79.05 2025-03-02 Common Stock 9350 D Stock Option (right to buy) 85.88 2025-07-01 Common Stock 20000 D Stock Option (right to buy) 22.73 2026-08-25 Common Stock 21047 D Stock Option (right to buy) 59.27 2027-03-01 Common Stock 4250 D Stock Option (right to buy) 58.43 2028-03-01 Common Stock 4500 D Stock Option (right to buy) 3.40 2029-10-30 Common Stock 35000 D Restricted Stock Units 2027-03-01 Common Stock 516 D Restricted Stock Units 2028-03-01 Common Stock 1688 D Restricted Stock Units 2029-02-01 Common Stock 14063 D Restricted Stock Units 2030-01-31 Common Stock 29000 D On January 10, 2014, the reporting person was granted 8,000 options. The options are fully vested and are immediately exercisable. On February 27, 2014, the reporting person was granted 30,000 options. The options are fully vested and are immediately exercisable. On March 2, 2015, the reporting person was granted 9,350 options. The options are fully vested and are immediately exercisable. On July 1, 2015, the reporting person was granted 20,000 options. The options are fully vested and are immediately exercisable. On August 25, 2016, the reporting person was granted 33,675 options. The options are fully vested and are immediately exercisable. On March 1, 2017, the reporting person was granted 4,250 options. The option vested as to 25% of the shares on March 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date. On March 1, 2018, the reporting person was granted 4,500 options. The option vested as to 25% of the shares on March 1, 2019, and the remainder vests in substantially equal installments over the 36 months immediately following such date. On October 30, 2019, the reporting person was granted 35,000 options. The option vests as to 25% of the shares on October 30, 2020, and the remainder vests in substantially equal installments over the 36 months immediately following such date. On March 1, 2017, the reporting person was granted 4,125 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. On March 1, 2018, the reporting person was granted 4,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vest on January 31, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Each Restricted Stock Unit represents the right to receive one share of Common Stock. Senior Vice President and Chief Scientific Officer /s/ Thomas C. Harding 2020-12-07